^
    18h
    Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=4, Completed, Weill Medical College of Cornell University | Recruiting --> Completed
    Trial completion
    |
    FLT3 (Fms-related tyrosine kinase 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4)
    |
    Cabometyx (cabozantinib tablet)
    21h
    Establishment of patient-derived 3D tumouroids: personalised medicine tools for renal cancer. (PubMed, Acta Biomater)
    Finally, tumouroids were subjected to treatment with Pazopanib (Votrient™), a tyrosine kinase inhibitor (TKI) used in the treatment of advanced RCC...Tumouroids mimic the original tumour and its microenvironment and elicit response to drugs that target both the tumour cells and the tumour microenvironment. This is a patient-specific in vitro tool that addresses the unmet clinical need for predicting an individual's response to therapy.
    Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    pazopanib
    1d
    Degradable Multifunctional Microspheres for Combined Thermotherapy-Embolization-Immune Activation Therapy of Hepatocellular Carcinoma. (PubMed, Adv Healthc Mater)
    Hence, we designed a degradable embolic microsphere (RegFe@MS) capable of simultaneously loading hydrophobic regorafenib and magnetic iron oxide nanoparticles...This strategy can not only inhibit the post-embolization angiogenic response but also maximally suppress the proliferation and invasion of residual tumors. Furthermore, RegFe@MS has demonstrated remarkable therapeutic effects in the rabbit orthotopic liver cancer model.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CCR6 (C-C Motif Chemokine Receptor 6)
    |
    Stivarga (regorafenib)
    1d
    INCB 84344-102: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Incyte Biosciences International Sàrl | Trial completion date: Jan 2026 --> Feb 2028 | Trial primary completion date: Jan 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RET (Ret Proto-Oncogene) • FGFR (Fibroblast Growth Factor Receptor) • BLM (BLM RecQ Like Helicase)
    |
    EGFR mutation • KIT mutation • FGFR mutation • RET mutation
    |
    Iclusig (ponatinib)
    2d
    NCI-2018-01836: Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • sorafenib • paclitaxel
    3d
    FRET-SAM: SAM_Med2D-based automatic FRET two-hybrid analysis. (PubMed, Comput Methods Programs Biomed)
    By enabling automated analysis of FRET images, FRET-SAM significantly enhances the efficiency and accuracy of FRET two-hybrid assays, while eliminating subjective bias. The capability of FRET-SAM to resolve drug-target interactions establishes it as a promising tool for drug discovery.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BCL2L1 (BCL2-like 1)
    |
    gefitinib • sorafenib • A-1331852
    3d
    QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    4d
    Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (clinicaltrials.gov)
    P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jan 2025 --> Apr 2027 | Trial primary completion date: Aug 2024 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    4d
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    4d
    Unravelling the Crosstalk: Anti-Fibrotic Agents and MAPK Inhibitors in the Treatment of Melanoma. (PubMed, Crit Rev Oncol Hematol)
    Targeting fibrotic pathways such as TGF-β, FGF, and PDGF signalling, with medications like nintedanib and pirfenidone, may help overcome the resistance mechanisms associated with MAPK inhibitor therapy. This review unravels the complex interactions between MAPK inhibitors and anti-fibrotic drugs in the treatment of melanoma, highlighting how they might work together to remodel the TME and overcome treatment resistance. Implementing this combinatorial method could lead to novel approaches for long-term melanoma control and provide a model for anti-fibrotic-based treatments for other solid cancers.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    nintedanib
    4d
    NINBOST2018: Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=20, Recruiting, University Hospital, Basel, Switzerland | Trial primary completion date: Aug 2025 --> Dec 2026 | Trial completion date: Aug 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    nintedanib
    4d
    Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) (clinicaltrials.gov)
    P2, N=6, Terminated, M.D. Anderson Cancer Center | N=58 --> 6 | Trial completion date: Dec 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Dec 2025; <75% Participation
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    fulvestrant • Augtyro (repotrectinib)